Inventiva’s lanifibranor meets the primary and key secondary endpoints in the Phase IIb NATIVE clinical trial in non-alcoholic steatohepatitis (NASH

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy